CROI 2016 Program at a Glance

Program and Agenda

Session TD-12 Themed Discussion

Ballroom B/C

Session S-5 Symposium

Ballroom A

CME

1:45 PM-2:45 PM It’s Complicated: Renal Function and STIs in PrEP Users Themed Discussion Leader Amanda Mocroft ,UniversityCollegeLondon,London,UnitedKingdom 866 Higher Cumulative TFV/FTC Levels in PrEP Associated With Decline in Renal Function Monica Gandhi 1 ; DavidV. Glidden 1 ; AlbertY. Liu 2 ; Howard Horng 1 ; K. R. Amico 3 ; Kathleen Mulligan 1 ; Sybil Hosek 4 ; Mauro Schechter 5 ; Kenneth H. Mayer 6 ; Robert Grant 1 ; for the iPrEx StudyTeam 1 UnivofCaliforniaSanFrancisco,SanFrancisco,CA,USA; 2 SanFrancisco DeptofPH,SanFrancisco,CA,USA; 3 UnivofMichiganSchofPH,Ann Arbor,MI,USA; 4 JohnH.Stroger JrHospofCookCounty,Chicago, IL,USA; 5 ProjetoPraçaOnze,UniversidadeFeddoRiode Janeiro,Riode Janeiro, Brazil; 6 TheFenway Inst,FenwayHlth,Boston,MA,USA 867 Changes in Renal Function AssociatedWith TDF/FTC PrEP Use in the US Demo Project AlbertY. Liu 1 ; EricVittinghoff 2 ; Peter L. Anderson 3 ; Stephanie Cohen 1 ; Susanne Doblecki-Lewis 4 ; Oliver Bacon 1 ;Wairimu Chege 5 ; Susan P. Buchbinder 1 ; Michael Kolber 4 ; Richard Elion 6 ; for the Demo Project Team 1 SanFranciscoDeptofPH,SanFrancisco,CA,USA; 2 UnivofCaliforniaSan Francisco,SanFrancisco,CA,USA; 3 UnivofColorado,Denver,CO,USA; 4 UnivofMiami,Miami,FL,USA; 5 DAIDS,NIAID,NIH,Bethesda,MD,USA; 6 GeorgeWashingtonUnivSchofMed,Washington,DC,USA 868 Rare Incidence of Proximal Tubular DysfunctionWith Tenofovir-Based Chemoprophylaxis Kenneth K. Mugwanya 1 ; Jared M. Baeten 1 ; Connie M. Celum 1 ; Deborah Donnell 2 ;Thomas Nickolas 3 ; Nelly R. Mugo 4 ; Andrea Branch 5 ; James K. Kairie 6 ; Allan Ronald 7 ; ChristinaWyatt 5 ; for the Partners PrEP StudyTeam 1 UnivofWashington,Seattle,WA,USA; 2 SCHARP,FredHutchinsonCancer RsrCntr,Seattle,WA,USA; 3 ColumbiaUniv,NewYork,NY,USA; 4 Kenya MedRsr Inst,Thika,Kenya; 5 IcahnSchofMedatMountSinai,NewYork, NY,USA; 6 UnivofNairobi,Nairobi,Kenya; 7 UnivofManitoba,Winnipeg, MB,Canada Implementation Suggest Changes to CDC Guidelines Sarit A. Golub 1 ; Stephanie Pena 2 ; Kailip Boonrai 3 ; Nora Douglas 2 ; Machel Hunt 2 ; Asa Radix 2 1 HunterColland theGradCntr,CityUnivofNewYork,NewYork,NY,USA; 2 Callen-LordeCommunityHlthCntr,NewYork,NY,USA; 3 HunterHIV/AIDS RsrTeam,HunterColl,NewYork,NY,USA 870 Quarterly STI Screening Optimizes STI Detection Among PrEP Users in the Demo Project Stephanie Cohen 1 ; EricVittinghoff 2 ; Susan S. Philip 1 ; Susanne Doblecki-Lewis 3 ; Oliver Bacon 1 ;Wairimu Chege 4 ; Richard Elion 5 ; Susan P. Buchbinder 1 ; Michael Kolber 3 ; AlbertY. Liu 1 1 SanFranciscoDeptofPH,SanFrancisco,CA,USA; 2 UnivofCalifornia SanFrancisco,SanFrancisco,CA,USA; 3 UnivofMiami,Miami,FL,USA; 4 DAIDS,NIAID,NIH,Bethesda,MD,USA; 5 GeorgeWashingtonUnivSchof Med,Washington,DC,USA 869 STI Data From Community-Based PrEP

4:00 PM-6:00 PM Reaching 90-90-90 and Beyond: Challenges and Innovations Target audience: This session is directed to clinicians, scientists, and public health practitioners who are interested in understanding the global HIV response targets, current status in terms of progress towards these targets and strategies that may enable their achievement. Level of knowledge: It is assumed that participants are familiar with basic concepts of the HIV global response and key elements of HIV programming. Objectives: At the completion of the session, participants will be able to: • Describe the issues to be addressed in order to achieve global targets for HIV diagnosis and ART initiation, adherence and retention • Describe innovations to help overcome the implementation challenges • Assess progress toward achievement of targets over time Conveners

Serge Eholie ,TreichvilleUniversity TeachingHospital,Abidjan, IvoryCoast Catherine A. Hankins ,Amsterdam Institute forGlobalHealthand Development,AmsterdamNetherlands 4:00 119 Option B+: A Stepping Stone to Universal Treatment Andreas Jahn ,MinistryofHlth,Lilongwe, Malawi 4:30 120 Missing But in Action: Where Are the Men? Helen Ayles ,LondonSchofHygiene&Trop Med,London,UK 5:00 121 Antiretroviral Therapy for Life: Understanding and Improving Retention Elvin H. Geng ,UnivofCaliforniaSan Francisco,SanFrancisco,CA,USA 5:30 122 Innovations in Antiretroviral Therapy Delivery Anna Grimsrud , IAS,CapeTown, SouthAfrica

Oral Sessions • Wednesday, February 24, 2016

40

CROI 2016